Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Receivables - Other: 2011-2025

Historic Receivables - Other for Lineage Cell Therapeutics (LCTX) over the last 8 years, with Sep 2025 value amounting to $549,000.

  • Lineage Cell Therapeutics' Receivables - Other was N/A to $549,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $549,000, marking a year-over-year change of. This contributed to the annual value of $581,000 for FY2022, which is 8.60% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Receivables - Other stood at $549,000, which was down 5.51% from $581,000 recorded in Q4 2022.
  • In the past 5 years, Lineage Cell Therapeutics' Receivables - Other ranged from a high of $581,000 in Q4 2022 and a low of $200,000 during Q2 2022.
  • Moreover, its 1-year median value for Receivables - Other was $549,000 (2025), whereas its average is $549,000.
  • Data for Lineage Cell Therapeutics' Receivables - Other shows a peak YoY increased of 8.60% (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows Lineage Cell Therapeutics' Receivables - Other stood at $535,000 in 2021, then rose by 8.60% to $581,000 in 2022, then reached $549,000 in 2025.
  • Its Receivables - Other was $549,000 in Q3 2025, compared to $581,000 in Q4 2022 and $545,000 in Q3 2022.